Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration.
about
Clinical and molecular models of glioblastoma multiforme survivalProtein signature for non-small cell lung cancer prognosis.Combined PTEN Mutation and Protein Expression Associate with Overall and Disease-Free Survival of Glioblastoma Patients.Surgical resection of malignant gliomas-role in optimizing patient outcome.p53, MDM2, eIF4E and EGFR expression in nasopharyngeal carcinoma and their correlation with clinicopathological characteristics and prognosis: A retrospective study.Reverse engineering of modified genes by Bayesian network analysis defines molecular determinants critical to the development of glioblastoma.Screening for EGFR amplifications with a novel method and their significance for the outcome of glioblastoma patients.Whole genome sequencing of glioblastoma multiforme identifies multiple structural variations involved in EGFR activationFactors associated with increased survival after surgical resection of glioblastoma in octogenarians.Whole genome sequence analysis links chromothripsis to EGFR, MDM2, MDM4, and CDK4 amplification in glioblastoma.Epidermal growth factor receptor is related to poor survival in glioblastomas: single-institution experience.Complete diagnostics and clinical approach for a female patient with unusual glioblastoma: A case study.Roles of pathologists in molecular targeted cancer therapy.Effect of epidermal growth factor receptor gene polymorphisms on prognosis in glioma patients.TP53 promoter methylation in primary glioblastoma: relationship with TP53 mRNA and protein expression and mutation status.Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis.Frequency and clinical significance of chromosome 7 and 10 aneuploidies, amplification of the EGFR gene, deletion of PTEN and TP53 genes, and 1p/19q deficiency in a sample of adult patients diagnosed with glioblastoma from Southern Brazil.Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase I inhibitor or radiation.Integrins and p53 pathways in glioblastoma resistance to temozolomide.Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy.Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients.Molecular classification defines 4 prognostically distinct glioma groups irrespective of diagnosis and grade.Pathological significance of epidermal growth factor receptor expression and amplification in human gliomas.MiR-181b modulates EGFR-dependent VCAM-1 expression and monocyte adhesion in glioblastoma.Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors.Adult cerebellar glioblastoma cases have different characteristics from supratentorial glioblastoma.Expression of p53 & epidermal growth factor receptor in glioblastoma.Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study.
P2860
Q33601633-ED373952-3C5F-48BA-A18D-EF161C0161ACQ33785608-C7C08F0C-D0CD-4389-A1FB-40AE4FEC5D06Q33912410-6B22E28B-6162-41C9-AC1A-F72FD1C7CCDFQ34324963-78DB93B4-0003-45C0-B75D-410EA41ACDA5Q34583151-191FC3BF-DA98-43E9-8CD7-E1269AA573F6Q34758639-998B1764-C84D-4ACF-8D38-66C7876550D7Q34769934-33185373-491C-4A25-98CF-364E8C96A10DQ35221471-3AFF76C0-3372-433B-A861-78F6812919B8Q35610849-82CDC9B4-93A6-4884-9C86-9540EE8C389CQ35995829-AA7F7C39-18EB-4FA3-8D55-60664D31CB54Q36463850-5D43788A-08F0-4F8E-BFDE-EF286149867EQ37001032-8FEBB5B3-D8AA-424B-BBB9-66C194A84735Q37627937-A4A3B11F-FD30-4083-8C57-7EDEDA30D7B1Q37665244-000C8DBC-3C32-4C5D-A6A1-C57544E257EDQ37667596-0DE634DE-04C7-4D86-AA2F-7A911882DF15Q37820417-A19E3911-7B73-4413-909C-46A20411D42DQ38601004-DF45918C-8430-4EB4-9508-D312770BDA55Q38960333-DE0210D1-F047-4916-A905-BF2B5101B757Q41630032-20AE13D6-90B5-4686-9DE7-09C80F9E6FE2Q45036488-6B2B98A3-178F-4590-8280-253D72ECB4A8Q46246365-FB25E572-DE94-4CFA-8202-AA6F12F18230Q48335626-05362F25-E64C-4F98-B905-9903D97A21C4Q48376998-4E366144-ABA4-4989-B04C-6894E6E07870Q50894719-9530DAD2-167C-4EBA-993D-055D9C2D0553Q50977877-F9650506-ED17-4EF1-8768-ADFFFE88E272Q51390064-B6E7FF76-899B-47C2-AF8B-221AA1FE4655Q55317834-2E70EEF5-2C32-44BC-AD03-8B4486038E79Q55463256-5A2BA3E2-CB64-4583-B8B5-A70CCE6377B1
P2860
Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Worse outcome in primary gliob ...... r receptor and p53 alteration.
@en
Worse outcome in primary gliob ...... r receptor and p53 alteration.
@nl
type
label
Worse outcome in primary gliob ...... r receptor and p53 alteration.
@en
Worse outcome in primary gliob ...... r receptor and p53 alteration.
@nl
prefLabel
Worse outcome in primary gliob ...... r receptor and p53 alteration.
@en
Worse outcome in primary gliob ...... r receptor and p53 alteration.
@nl
P2093
P356
P1476
Worse outcome in primary gliob ...... or receptor and p53 alteration
@en
P2093
Angel Rodríguez de Lope
Concepción Fiaño
Elisa Pérez-Magán
José-Luis Hernández-Moneo
Manuela Mollejo
Yolanda Campos-Martín
Yolanda Ruano
P304
P356
10.1309/AJCP64YBDVCTIRWV
P407
P577
2009-02-01T00:00:00Z